|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Sapari NS, Loh M, Vaithilingam A and Soong
R: Clinical potential of DNA methylation in gastric cancer: a
meta-analysis. PLoS One. 7:e362752012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
González CA and Agudo A: Carcinogenesis,
prevention and early detection of gastric cancer: where we are and
where we should go. Int J Cancer. 130:745–753. 2012.PubMed/NCBI
|
|
4
|
Yamamoto E, Suzuki H, Takamaru H, Yamamoto
H, Toyota M and Shinomura Y: Role of DNA methylation in the
development of diffuse-type gastric cancer. Digestion. 83:241–249.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamashita K, Sakuramoto S and Watanabe M:
Genomic and epigenetic profiles of gastric cancer: potential
diagnostic and therapeutic applications. Surg Today. 41:24–38.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang CH, Tang CW, Liu CL and Tang LP:
Inhibitory effect of octreotide on gastric cancer growth via MAPK
pathway. World J Gastroenterol. 9:1904–1908. 2003.PubMed/NCBI
|
|
7
|
Tang C, Liu C, Zhou X and Wang C: Enhanced
inhibitive effects of combination of rofecoxib and octreotide on
the growth of human gastric cancer. Int J Cancer. 112:470–474.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xie Y, Chen S, Wang CH and Tang CW: SOM230
combined with celecoxib prolongs the survival in nude mice with
HepG-2 xenografts. Cancer Biol Ther. 12:86–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jackson K, Soutto M, Peng D, Hu T, Marshal
D and El-Rifai W: Epigenetic silencing of somatostatin in gastric
cancer. Dig Dis Sci. 56:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fuchs CS and Mayer RJ: Gastric carcinoma.
N Engl J Med. 333:32–41. 1995. View Article : Google Scholar
|
|
11
|
Abbaszadegan MR, Moaven O, Sima HR,
Ghafarzadegan K, A’rabi A, Forghani MN, Raziee HR, Mashhadinejad A,
Jafarzadeh M, Esmaili-Shandiz E and Dadkhah E: p16 promoter
hypermethylation: a useful serum marker for early detection of
gastric cancer. World J Gastroenterol. 14:2055–2060. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fleisher AS, Esteller M, Tamura G, Rashid
A, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Nishizuka S, et al:
Hypermethylation of the hMLH1 gene promoter is associated with
microsatellite instability in early human gastric neoplasia.
Oncogene. 20:329–335. 2001. View Article : Google Scholar
|
|
13
|
Homma N, Tamura G, Honda T, Matsumoto Y,
Nishizuka S, Kawata S and Motoyama T: Spreading of methylation
within RUNX3 CpG island in gastric cancer. Cancer Sci. 97:51–56.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang YH, Lee HS and Kim WH: Promoter
methylation and silencing of PTEN in gastric carcinoma. Lab Invest.
82:285–291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zou B, Chim CS, Zeng H, Leung SY, Yang Y,
Tu SP, Lin MC, Wang J, He H, Jiang SH, et al: Correlation between
the single-site CpG methylation and expression silencing of the
XAF1 gene in human gastric and colon cancers. Gastroenterology.
131:1835–1843. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gardiner-Garden M and Frommer M: CpG
Islands in vertebrate genomes. J Mol Biol. 196:261–282. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bird AP: CpG-rich islands and the function
of DNA methylation. Nature. 321:209–213. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao B, Yang P, Yang J and Cai D: A
randomized trial of somatostatin to regulate the VEGFs/VEGFRs in
patients with gastric cancer. Hepatogastroenterology. 58:1425–1430.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin Z, Mori Y, Hamilton JP, Olaru A, Sato
F, Yang J, Ito T, Kan T, Agarwal R and Meltzer SJ: Hypermethylation
of the somatostatin promoter is a common, early event in human
esophageal carcinogenesis. Cancer. 112:43–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mori Y, Cai K, Cheng Y, Wang S, Paun B,
Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, et al: A genome-wide
search identifies epigenetic silencing of somatostatin,
tachykinin-1, and 5 other genes in colon cancer. Gastroenterology.
131:797–808. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Torrisani J, Hanoun N, Laurell H, Lopez F,
Maoret JJ, Souque A, Susini C, Cordelier P and Buscail L:
Identification of an upstream promoter of the human somatostatin
receptor, hSSTR2, which is controlled by epigenetic modifications.
Endocrinology. 149:3137–3147. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Marquez M, Nilsson S and Holmberg
AR: Incubation with somatostatin, 5-aza decitabine and trichostatin
up-regulates somatostatin receptor expression in prostate cancer
cells. Oncol Rep. 20:151–154. 2008.PubMed/NCBI
|
